Announcement of explanation on the Company’s criminal lawsuit against Next Magazine

OBI-833, the cancer therapeutic vaccine, has met the primary safety indicators in Phase I clinical trial for US and Taiwan
April 6, 2017
Announcement of explanation on the first instance judgment of the civil action between the Company against “Next Magazine”
April 26, 2017
  1. Parties to the legal matter: OBI Pharma, Inc.
  2. Name of the court or disposing agency: Shihlin District Prosecutors Office, Taiwan
  3. Reference/case numbers of relevant documents: 2017 Zhen-Zi No. 5025, 5026
  4. Date of occurrence of the event: April 17, 2017
  5. Background and circumstances of the matter (including the property/subject matter under dispute):
    (1) Regarding the continuous and malicious false reports by Next Magazine, OBI filed a criminal lawsuit against relevant employees on April 7 and September 8, 2016 to safeguard the company’s legal rights.
    (2)OBI received a final decision of dismissal of the case by Shihlin District Prosecutors Office.
  6. Course and progression of handling of the matter: OBI will take necessary legal actions after discussion with the attorneys.
  7. Effect on company finances and business and estimated monetary amount of the effect: None
  8. Countermeasures and status of amelioration: None
  9. Any other matters that need to be specified: The operation and financial status of the company remain normal and unaffected.